有证据表明,氨酸- ангиотензин系统在酸盐耐受性方面的因果作用
1Department of Medicine, Emory University School of Medicine, Veterans Administration Hospital, Atlanta, GA, USA.
Circulation
|June 22, 1999
概括
耐受性酸甘 (NTG) 治疗与血管超氧化物产生增加有关,由血管新生素II和内甲蛋白-1通路驱动. 阻止这些通路可以防止耐受性,并恢复NTG的有效性.
科学领域:
- 心血管药理学心血管药理学
- 血管生物学 血管生物学
- 酸盐耐受性机制
背景情况:
- 酸甘油 (NTG) 治疗增加了血管内甲蛋白-1 (ET-1) 和超氧化物 (O2.-) 的产生,可能是通过血管新生素II.
- 在早期NTG疗法期间,氨酸-血管酶系统被激活.
- 假设:在NTG治疗期间, ангиотензинII或ET-1会增加血管O2的产生.
研究的目的:
- 调查血管素II和ET-1在酸盐耐受性发展中的作用.
- 确定NTG疗法对血管O2-生产和氨酸-血管新生素系统的影响.
- 评估AT1和ET-1受体阻断在预防NTG耐受性的有效性.
主要方法:
- 新西兰白用NTG贴片治疗了3天.
- 评估了血雷宁活性,AT1受体表达,血管ACE活性和NTG血管扩张功效.
- 测量了使用素增强化学发光的血管O2-生产.
- 服用AT1受体对抗剂洛萨坦和ET-1受体阻断剂博森坦.
主要成果:
- 治疗NTG增加了血内活性和血管O2-生产,导致NTG放松 (耐受性) 减弱.
- 耐受性与增加的AT1受体mRNA和ACE活性有关.
- 洛萨坦剂量取决于正常化的O2生产,防止NTG耐受性和交叉耐受性.
- 博森坦也表现出类似的效果,但效果不那么明显.
结论:
- ангиотензин II 在酸盐耐受性发展中起着显著的病理生理作用.
- 恩多林-1有助于酸盐耐受性,尽管比血管新生素II的作用要小.
- 在NTG治疗期间,AT1和ET-1受体阻断对耐受性和O2-产生产生积极影响.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...